Company intelligence / Profile preview

Zhejiang Baili Pharmaceutical

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Sichuan Biokin Pharmaceutical, formerly known as Baili Pharmaceutical, is a clinical-stage biopharmaceutical company based in Chengdu, China. It is dedicated to the research, development, manufacturing, and commercialization of innovative therapies, primarily focusing on oncology with a strong emphasis on proprietary antibody-drug conjugates (ADCs) and small molecules. Their lead asset, BL-B01D1, a bispecific HER3/EGFR ADC, is in late-stage clinical development.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate (ADC)Monoclonal antibodySmall molecule
Industry: Biotech

Partnerships

Bristol Myers Squibb (BMS)

Beyond the preview

Go deeper on Zhejiang Baili Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Baili Pharmaceutical.

Explore the full profile